Last Updated: 14 Sep 2024
Executive Summary
Bioventus Inc. (BVS) is a medical device company that develops and commercializes clinical treatments that enhance the body's natural healing process. The company has a market capitalization of $711.19 million and its latest stock price is $11.17. Bioventus has a positive PEGRatio of 2.142, indicating potential for future growth. However, the company's negative EPS and Return on Equity suggest current financial challenges.
Company Overview
Bioventus Inc. is headquartered in Durham, North Carolina. The company focuses on developing and commercializing clinical treatments in the areas of orthopedics, wound care, and chronic pain. Bioventus has a global presence with operations in the United States and internationally.
Fundamental Analysis
Revenue: Bioventus reported revenue of $536.89 million in the trailing twelve months (TTM), representing a 10.3% increase year-over-year.
Earnings: The company reported a net loss of $42.5 million in the TTM, resulting in an EPS of -$0.65.
Profitability: Bioventus' gross profit margin is 56.4%, while its operating margin is 10.1%. The company's net profit margin is -7.82%.
Balance Sheet: Bioventus has total assets of $953.7 million and total liabilities of $672.6 million. The company has a book value of $2.316 per share.
Technical Analysis
Moving Averages: Bioventus' 50-day moving average is $8.08, while its 200-day moving average is $5.88. The stock is currently trading above both moving averages.
Support and Resistance: The stock has support at $10.00 and resistance at $12.00.
Relative Strength Index (RSI): The RSI is currently at 55.36, indicating that the stock is in a neutral zone.
Short Term Outlook
In the short term, Bioventus is expected to continue to face challenges due to its negative earnings and low profit margins. However, the company's positive revenue growth and PEGRatio suggest potential for improvement. The stock is currently trading above its moving averages and has support at $10.00.
Long Term Outlook
In the long term, Bioventus' growth potential will depend on its ability to improve its profitability and expand its market share. The company's focus on developing innovative clinical treatments could drive future growth. However, competition in the medical device industry is intense, and Bioventus will need to execute effectively to achieve its long-term goals.
Analyst Recommendations
Analysts have mixed opinions on Bioventus. Two analysts recommend buying the stock, while one analyst recommends selling. The average analyst target price is $12.00.
